| Cell line | Species | Tissue | Culture medium | Cencentration |
|---|---|---|---|---|
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 2000 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| 293 | human | kidney; fetal | Minimal essential medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 150 (μg/ml) |
| 293 | human | kidney; fetal | Minimal essential medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 450 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 500 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 700 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| AtT20 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 293 | human | kidney; fetal | Minimal essential medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 350 (μg/ml) |
| RBL | rat | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 250 (μg/ml) |
| Non-CHO | RPMI 1640 Medium | 800 (μg/ml) | ||
| NCI-H1299 | human | lymph node (metastasis); large cell neuroendocrine carcinoma (lung primary) | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 143B | human | bone; osteosarcoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 100 (units/ml) |
| Saos-2 | human | bone; osteosarcoma | Dulbecco's modified Eagle's medium | 300 (μg/ml) |
| E11 (HCT-8 variant) | human | colon | RPMI 1640 Medium | 800 (μg/ml) |
| A549 | human | Lungcarcinoma | RPMI 1640 Medium | 700 (μg/ml) |
| A549 | human | Lungcarcinoma | RPMI 1640 Medium | 500 (μg/ml) |
| D3 | Dulbecco's modified Eagle's medium | 1500 (μg/ml) | ||
| FE-8 | Dulbecco's modified Eagle's medium | 200 (μg/ml) | ||
| AR42J | rat | exocrine pancreas; tumor | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| NG108-15 | mouse/rat | brain; glial cell; neuron; glioblastoma; neuroblastoma (hybrid) | Dulbecco's modified Eagle's medium | 1000-1300 (μg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| PC12 | Dulbecco's modified Eagle's medium | 1 (mg/ml) | ||
| WEHI-231 | mouse | B lymphocyte; lymphoma | RPMI 1640 Medium | 600 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 100 (μg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 1.5 (μg/ml) |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| A9 L | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| CD40-B | Iscove's modified Dulbecco's medium | 1000 (μg/ml) | ||
| A9 | mouse/mouse | hybridoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| PRO | RPMI 1640 Medium | 1200 (μg/ml) | ||
| HCC | Dulbecco's modified Eagle's medium | 300 (μg/ml) | ||
| BEL-7402 | RPMI 1640 Medium | 500 (μg/ml) | ||
| SPC-A1 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| HCC | Dulbecco's modified Eagle's medium | 200 (μg/ml) | ||
| Hep G2 | human | liver; hepatocellular carcinoma | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| Hep3B | Minimal essential with Hank's salts | 600 (μg/ml) | ||
| BARF0 | RPMI 1640 Medium | 400 (μg/ml) | ||
| 293 | human | kidney; fetal | RPMI 1640 Medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | RPMI 1640 Medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | RPMI 1640 Medium | 800 (μg/ml) |
| B95-8 | Iscove's minimal essential medium | 500 (μg/ml) | ||
| BT-474 | human | mammary gland; ductal carcinoma | Dulbecco's modified Eagle's medium | 4000 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| DG75 | RPMI 1640 Medium | 700 (μg/ml) | ||
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| C666 | RPMI 1640 Medium | 200 (μg/ml) | ||
| T2 (174 x CEM.T2) | human/human | lymphoblast cell hybrid | RPMI 1640 Medium | 600 (μg/ml) |
| Akata | RPMI 1640 Medium | 700 (μg/ml) | ||
| 293 | human | kidney; fetal | RPMI 1640 Medium | 700 (μg/ml) |
| BL | RPMI 1640 Medium | 300 (μg/ml) | ||
| PEL | RPMI 1640 Medium | 300 (μg/ml) | ||
| A904L | RPMI 1640 Medium | 300 (μg/ml) | ||
| TW01 | RPMI 1640 Medium | 1000 (μg/ml) | ||
| B95-8 | RPMI 1640 Medium | 3000 (μg/ml) | ||
| B95-8 | Fetal bovine serum/ Fetal Calf Serum | 800000 (μg/ml) | ||
| HONE-1 | Dulbecco's modified Eagle's medium | 200 (μg/ml) | ||
| HeLa | human | cervix; adenocarcinoma | 800 (μg/ml) | |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | 800 (mg/ml) | |
| A9 | mouse/mouse | hybridoma | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| HONE-1 | Dulbecco's modified Eagle's medium | 1 (mg/ml) | ||
| PA317 | mouse | embryo; amphotropic retroviral packaging line | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| EC9706 | 500 (μg/ml) | |||
| SLMT-1 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| TGR-1 | 800 (μg/ml) | |||
| RD | human | muscle; rhabdomyosarcoma | Dulbecco's modified Eagle's medium | 100 (μg/ml) |
| A9 | mouse/mouse | hybridoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| PC-3 | human | bone (metastasis); adenocarcinoma (prostate primary) | Ham’s F-12 nutrient mixture | 1000 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 1500 (μg/ml) |
| Bosc23 | Dulbecco's modified Eagle's medium | 300 (μg/ml) | ||
| 3T3 | mouse | embryonic fibroblast | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 650 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 650 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| LNCaP | human | prostatic adenocarcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 3T3-L1-TET | Dulbecco's modified Eagle's medium | 35 (μg/ml) | ||
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| PC12 | Dulbecco's modified Eagle's medium | 250 (μg/ml) | ||
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| MDA-468 | human | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | |
| BT-20 | human | mammary gland; carcinoma | Eagle's minimal essential medium | 400 (μg/ml) |
| MCF-12A | human | mammary gland | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| GP+E-86 | mouse | embryo; amphotropic retroviral packaging line | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| L02 | human | Dulbecco's modified Eagle's medium | 600 (μg/ml) | |
| CHO | hamster, Chinese | ovary | α-modified minimal essential medium | 800 (μg/ml) |
| GLC-82 | human | lung | RPMI 1640 Medium | 500 (μg/ml) |
| ARIP | rat | exocrine pancreas; tumor | 400 (μg/ml) | |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HCC | Eagle's minimal essential medium | 800 (μg/ml) | ||
| AN3 CA | human | lymph node (metastasis); adenocarcinoma (endometrium primary) | 550 (μg/ml) | |
| BeWo | human | placenta; choriocarcinoma | Ham’s F-12 nutrient mixture | 300 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Eagle's minimal essential medium | 500 (μg/ml) |
| BeWo | human | placenta; choriocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| CHO | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 500 (μg/ml) |
| BeWo | human | placenta; choriocarcinoma | 800 (μg/ml) | |
| BOSC | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| BeWo | human | placenta; choriocarcinoma | Ham’s F-12 nutrient mixture | 500 (μg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| JEG-3 | human | placenta; choriocarcinoma | Eagle's minimal essential medium | 1000 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 1000 (μg/ml) |
| GH4 | rat | Dulbecco's modified Eagle's medium | 800 (μg/ml) | |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| SK-HEP-1 | human | ascites (metastasis); adenocarcinoma (liver primary) | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| GH3 | rat | pituitary tumor | Ham's F-10 | 800 (μg/ml) |
| AtT-20 | mouse | pituitary tumor | Dulbecco's modified Eagle's medium | 300 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| C6 | rat | brain; glioma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| C2C12 | mouse | muscle | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| ME-180 | human | omentum (metastasis); epidermoid carcinoma (cervix primary) | RPMI 1640 Medium | 1000 (μg/ml) |
| A549 | human | Lungcarcinoma | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| U-87 MG | Dulbecco's modified Eagle's medium | 750 (μg/ml) | ||
| BT-549 | human | mammary gland; ductal carcinoma | Dulbecco's modified Eagle's medium | 750 (μg/ml) |
| JEG-3 | human | placenta; choriocarcinoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| C166 | mouse (transgenic) | yolk sac; endothelial cell differentiation model; stem cell feeder layer | Minimal essential medium | 800 (μg/ml) |
| T-47D | human | pleural effusion (metastasis); ductal carcinoma (mammary gland primary) | RPMI 1640 Medium | 800 (μg/ml) |
| BT-20 | human | mammary gland; carcinoma | Eagle's minimal essential medium | 250 (μg/ml) |
| A20 | mouse | B lymphocyte; reticulum cell sarcoma | RPMI 1640 Medium | 400 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | 400 (μg/ml) | |
| DU 145 | human | brain (metastasis); carcinoma (prostate primary) | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| BT | bovine | turbinate | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| BeWo | human | placenta; choriocarcinoma | Ham’s F-12 nutrient mixture | 200 (μg/ml) |
| Hep G2 | human | liver; hepatocellular carcinoma | 400 (μg/ml) | |
| HeLa | human | cervix; adenocarcinoma | Eagle's minimal essential medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| LLC-PK1 | pig | kidney | Charcoal-stripped fetal bovine serum | 1500 (μg/ml) |
| OK | opossum | kidney (cortex); proximal tubule | DMEM + F12 medium | 400 (μg/ml) |
| BeWo | human | placenta; choriocarcinoma | Ham’s F-12 nutrient mixture | 1 (mg/ml) |
| BRL 3A | rat | liver | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| BRL 3A | rat | liver | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| BRL 3A | rat | liver | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| COLO 320HSR | human | colon; colorectal adenocarcinoma | RPMI 1640 Medium | 400 (μg/ml) |
| BALB/3T3 clone A31 | mouse | embryo | Dulbecco's modified Eagle's medium | 250 (μg/ml) |
| T-47D | human | pleural effusion (metastasis); ductal carcinoma (mammary gland primary) | RPMI 1640 Medium | 400 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 650 (μg/ml) |
| BALB/3T3 clone A31 | mouse | embryo | Dulbecco's modified Eagle's medium | 2000 (μg/ml) |
| 3T3 | mouse | embryonic fibroblast | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| BALB/3T3 clone A31 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| Saos-2 | human | bone; osteosarcoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| U-87 MG | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| CHO | hamster, Chinese | ovary | α-modified minimal essential medium | 400 (μg/ml) |
| MG-63 | human | bone; osteosarcoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| SW 1353 | human | bone; chondrosarcoma | α-modified minimal essential medium | 500 (μg/ml) |
| A-204 | human | muscle; rhabdomyosarcoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| MC3T3-E1 Subclone 4 | mouse | bone (metastasis); osteosarcoma (femur primary) | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| BALB/3T3 clone A31 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| MDA-MB-436 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | α-modified minimal essential medium | 125 (μg/ml) |
| BALB/3T3 clone A31 | mouse | embryo | Dulbecco's modified Eagle's medium | 100 (μg/ml) |
| M1 | mouse | myeloblast; myeloid leukemia | Dulbecco's modified Eagle's medium | 100 (μg/ml) |
| Rat1-R12 | rat | connective tissue | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| Rat1-R12 | rat | connective tissue | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| BALB/3T3 clone A31 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 500 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | α-modified minimal essential medium | 800 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 780 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 780 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Eagle's minimal essential medium | 1000 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | 500 (μg/ml) | |
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Eagle's minimal essential medium | 800 (μg/ml) |
| NCI-H1299 | human | lymph node (metastasis); large cell neuroendocrine carcinoma (lung primary) | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | GMEM medium | 1 (mg/ml) |
| MDA-MB-468 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Minimal essential medium | 2 (μg/ml) |
| HBL-100 | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| U-87 MG | α-modified minimal essential medium | 600 (μg/ml) | ||
| JEG-3 | human | placenta; choriocarcinoma | Eagle's minimal essential medium | 1500 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | DMEM + F12 medium | 600 (μg/ml) |
| K-562 | human | pleural effusion (metastatic); chronic myelo-genous leukemia (bone marrow primary) | RPMI 1640 Medium | 600 (μg/ml) |
| N2a | DMEM + F12 medium | 200 (μg/ml) | ||
| B16 | Murine | melanoma | DMEM + F12 medium | 600 (μg/ml) |
| JEG-3 | human | placenta; choriocarcinoma | Eagle's minimal essential medium | 300 (μg/ml) |
| NCI-H295 | human | adrenal gland; cortex adrenocortical carcinoma | 400 (μg/ml) | |
| CHO | hamster, Chinese | ovary | Eagle's minimal essential medium | 600 (μg/ml) |
| B95-8 | RPMI 1640 Medium | 0.5 (μg/ml) | ||
| Akata | RPMI 1640 Medium | 400 (μg/ml) | ||
| A904L | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| B95-8 | RPMI 1640 Medium | 1200 (μg/ml) | ||
| BJAB | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| B95-8 | RPMI 1640 Medium | 600 (μg/ml) | ||
| Bing | human | kidney; amphotropic retroviral packaging line | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 3T3 | mouse | embryonic fibroblast | 800 (μg/ml) | |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| CHO | hamster, Chinese | ovary | DMEM + F12 medium | 800 (μg/ml) |
| MDA-MB-231 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Eagle's minimal essential medium | 400 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Eagle's minimal essential medium | 400 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 300 (μg/ml) |
| PANC-1 | human | pancreas (duct); epithelioid carcinoma | Minimal essential medium | 550 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | DMEM + F12 medium | 230 (μg/ml) |
| A431NS | human | epidermis; epidermoid carcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Minimal essential medium | 1 (mg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| BJ | human | skin (foreskin) | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| A253 | human | epidermis; epidermoid carcinoma | RPMI 1640 Medium | 800 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 1000 (μg/ml) |
| LNCaP | human | prostatic adenocarcinoma | RPMI 1640 Medium | 1000 (μg/ml) |
| LNCaP | human | prostatic adenocarcinoma | RPMI 1640 Medium | 1000 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 100 (μg/ml) |
| COS-7 | monkey, African green | kidney | RPMI 1640 Medium | 3000 (μg/ml) |
| HT-1080 | human | connective tissue; fibrosarcoma | RPMI 1640 Medium | 400 (μg/ml) |
| LNCaP | human | prostatic adenocarcinoma | RPMI 1640 Medium | 1500 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 50000 (μg/ml) |
| NIH3T3 | mouse | embryo | DMEM + F12 medium | 1500 (μg/ml) |
| AGS | human | stomach; gastric adenocarcinoma | RPMI 1640 Medium | 400 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| MCF 10A | human | mammary gland; fibrocystic disease | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| MCF 10A | human | mammary gland; fibrocystic disease | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| A-431 | human | epidermis; epidermoid carcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| A-431 | human | epidermis; epidermoid carcinoma | Minimal essential medium | 400 (μg/ml) |
| A-431 | human | epidermis; epidermoid carcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| PC12 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 1500 (μg/ml) |
| DT40 | chicken | bursa; lymphoma | RPMI 1640 Medium | 350 (μg/ml) |
| DT40 | chicken | bursa; lymphoma | RPMI 1640 Medium | 500 (μg/ml) |
| NRK-52E | rat | kidney | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | 10 (μg/ml) | |
| NIH/3T3 | mouse | embryo | Ham’s F-12 nutrient mixture | 1000 (μg/ml) |
| MDCK (NBL-2) | dog | kidney | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| A-431 | human | epidermis; epidermoid carcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| GP+envAM-12 | mouse | embryo; amphotropic retroviral packaging line | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| RAW 264.7 | mouse | monocyte; macrophage; AMLV-induced tumor | 2500 (μg/ml) | |
| NIH/3T3 | mouse | embryo | 600 (μg/ml) | |
| PT67 | mouse | embryo; amphotropic retroviral packaging line | 500 (μg/ml) | |
| MDCK (NBL-2) | dog | kidney | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| CHO | hamster, Chinese | ovary | 500 (μg/ml) | |
| U-2 OS | human | bone; osteosarcoma | RPMI 1640 Medium | 600 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | 700 (μg/ml) | |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 800 (μg/ml) |
| A-431 | human | epidermis; epidermoid carcinoma | α-modified minimal essential medium | 800 (μg/ml) |
| A-431 | human | epidermis; epidermoid carcinoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 800 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | 400 (μg/ml) | |
| CHO-K1 | hamster, Chinese | ovary | 800 (μg/ml) | |
| NIH3T3 | mouse | embryo | Earle’s balanced salt solution medium | 1000 (μg/ml) |
| LNCaP | human | prostatic adenocarcinoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 500 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| PC12 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 2000 (μg/ml) |
| C2C12 | mouse | muscle | Dulbecco's modified Eagle's medium | 4000 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 800 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 70 (μg/ml) |
| MDCK (NBL-2) | dog | kidney | Eagle's minimal essential medium | 400 (μg/ml) |
| STO | mouse | embryo | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 700 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 600 (μg/ml) |
| ES cell | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| CHO-K1 | hamster, Chinese | ovary | DMEM + F12 medium | 800 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 800 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 800 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| H9 | human | RPMI 1640 Medium | 1000 (μg/ml) | |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 75 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 500 (μg/ml) |
| NRK | rat | kidney | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| COS-7 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| GP+envAM-12 | mouse | embryo; amphotropic retroviral packaging line | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| H9 | human | RPMI 1640 Medium | 400 (μg/ml) | |
| SCC-15 | human | tongue; squamous cell carcinoma | 500 (μg/ml) | |
| RGC-5 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HT-1080 | human | connective tissue; fibrosarcoma | Dulbecco's modified Eagle's medium | 250 (μg/ml) |
| GH3 | rat | pituitary tumor | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 350 (μg/ml) |
| NIH3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| BJAB | RPMI 1640 Medium | 600 (μg/ml) | ||
| hESCs | KO-DMEM | 2000 (μg/ml) | ||
| CHO-K1 | hamster, Chinese | ovary | DMEM + F12 medium | 500 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | 800 (μg/ml) | |
| CHO-K1 | hamster, Chinese | ovary | α-modified minimal essential medium | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 2000 (μg/ml) |
| GH3 | rat | pituitary tumor | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | DMEM / F 12 medium | 150 (μg/ml) |
| CD38 | RPMI 1640 Medium | 800 (μg/ml) | ||
| H9 | human | Dulbecco's modified Eagle's medium | 750 (μg/ml) | |
| P19 | mouse | embryo; teratocarcinoma; embryonic carcinoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Minimal essential medium | 800 (μg/ml) |
| GH3 | rat | pituitary tumor | DMEM + F12 medium | 1 (mg/ml) |
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| GH3 | rat | pituitary tumor | DMEM + F12 medium | 1000 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | DMEM + F12 medium | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | DMEM + F12 medium | 200 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 1 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | RPMI 1640 Medium | 500 (μg/ml) |
| COS-7 | monkey, African green | kidney | RPMI 1640 Medium | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 400 (μg/ml) |
| SCC-25 | human | tongue; squamous cell carcinoma | DMEM + F12 medium | 400 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 400 (μg/ml) |
| NIH3T3 | mouse | embryo | 400 (μg/ml) | |
| GH3 | rat | pituitary tumor | Dulbecco's modified Eagle's medium | 1 (μg/ml) |
| GH3 | rat | pituitary tumor | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| CHO | hamster, Chinese | ovary | α-modified minimal essential medium | 375 (μg/ml) |
| GH3 | rat | pituitary tumor | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| PT67 | mouse | embryo; amphotropic retroviral packaging line | DMEM + F12 medium | 800 (μg/ml) |
| CHO | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 1000 (μg/ml) |
| MDA-MB-231 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| MCF 10A | human | mammary gland; fibrocystic disease | DMEM / F 12 medium | 0.75 (μg/ml) |
| JEG-3 | human | placenta; choriocarcinoma | α-modified minimal essential medium | 400 (μg/ml) |
| 32D Clone 3 | mouse | bone marrow | RPMI 1640 Medium | 600 (μg/ml) |
| 32D Clone 3 | mouse | bone marrow | RPMI 1640 Medium | 2000 (μg/ml) |
| LS 174T | human | colon; colorectal adenocarcinoma | RPMI 1640 Medium | 800 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| HeLa S3 | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| DLD-1 | human | colon; colorectal adenocarcinoma | RPMI 1640 Medium | 400 (μg/ml) |
| SH-SY5Y | human | bone marrow (metastasis); neuroblastoma (brain primary) | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | 500 (μg/ml) | |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 250 (μg/ml) |
| CRFK | cat | kidney (cortex) | RPMI 1640 Medium | 500 (μg/ml) |
| D17 | dog | bone; osteosarcoma | RPMI 1640 Medium | 600 (μg/ml) |
| JEG-3 | human | placenta; choriocarcinoma | DMEM / F 12 medium | 250 (μg/ml) |
| BeWo | human | placenta; choriocarcinoma | Dulbecco's modified Eagle's medium | 750 (μg/ml) |
| JAR | human | placenta; choriocarcinoma | 1000 (μg/ml) | |
| JEG-3 | human | placenta; choriocarcinoma | 750 (μg/ml) | |
| MDA-MB-231 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Minimal essential medium | 400 (μg/ml) |
| JEG-3 | human | placenta; choriocarcinoma | Minimal essential medium | 400 (μg/ml) |
| 3T3-L1 | mouse | embryo | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| BT-20 | human | mammary gland; carcinoma | RPMI 1640 Medium | 1200 (μg/ml) |
| BT-20 | human | mammary gland; carcinoma | RPMI 1640 Medium | 400 (μg/ml) |
| JEG-3 | human | placenta; choriocarcinoma | 100 (μg/ml) | |
| CHO | hamster, Chinese | ovary | 500 (μg/ml) | |
| C2C12 | mouse | muscle | 500 (μg/ml) | |
| 293 | human | kidney; fetal | 600 (μg/ml) | |
| HeLa | human | cervix; adenocarcinoma | 500 (μg/ml) | |
| Hep3B | 600 (μg/ml) | |||
| Hep G2 | human | liver; hepatocellular carcinoma | 500 (μg/ml) | |
| NIH/3T3 | mouse | embryo | 1000 (μg/ml) | |
| BALB/3T3 clone A31 | mouse | embryo | Dulbecco's modified Eagle's medium | 1500 (μg/ml) |
| Rat1-R12 | rat | connective tissue | 1500 (μg/ml) | |
| 293T | human | Kidney (embryonic) | 500 (μg/ml) | |
| GP+E-86 | mouse | embryo; amphotropic retroviral packaging line | 1000 (μg/ml) | |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| CHO | hamster, Chinese | ovary | α-modified minimal essential medium | 500 (μg/ml) |
| U-2 OS | human | bone; osteosarcoma | 500 (μg/ml) | |
| Sf9 | armyworm, fall | ovary | SF900 II serum free medium | 350 (μg/ml) |
| H9 | human | Dulbecco's modified Eagle's medium | 400 (μg/ml) | |
| Saos-2 | human | bone; osteosarcoma | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| SC | human | peripheral blood; macrophage; monocyte | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| JB6 Cl 41-5a | mouse | skin (epidermis); chemically transformed | Eagle's minimal essential medium | 800 (μg/ml) |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| LMH | chicken | liver; hepatocellular carcinoma | DMEM / F 12 medium | 800 (μg/ml) |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| SW480 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| KB | human | HeLa contaminant | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | 600 (μg/ml) | |
| NIH/3T3 | mouse | embryo | 2 (mg/ml) | |
| 293 | human | kidney; fetal | Minimal essential medium | 800 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 150 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | Dulbecco's modified Eagle's medium | 62.5 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | 750 (μg/ml) | |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 1000 (μg/ml) |
| RAW 264.7 | mouse | monocyte; macrophage; AMLV-induced tumor | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| DLD-1 | human | colon; colorectal adenocarcinoma | RPMI 1640 Medium | 1000 (μg/ml) |
| HEp-2 | human | HeLa contaminant | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| PA317 | mouse | embryo; amphotropic retroviral packaging line | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| A549 | human | Lungcarcinoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | Dulbecco's modified Eagle's medium | 1 (mg/ml) |
| HuT 78 | human | T lymphocyte; cutaneous; lymphoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | 1000 (μg/ml) | |
| A-498 | human | kidney; carcinoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Iscove's modified Dulbecco's medium | 400 (μg/ml) |
| BT-474 | human | mammary gland; ductal carcinoma | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| BHK-21 (C-13) | hamster, Syrian golden | kidney | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| T24 | human | urinary bladder; transitional cell carcinoma | Dulbecco's modified Eagle's medium | 50 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| Clone 9 | rat | liver | DMEM / F 12 medium | 600 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 425 (μg/ml) |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 300 (μg/ml) |
| U-937 | human | macrophage; histiocytic lymphoma | RPMI 1640 Medium | 500 (μg/ml) |
| DLD-1 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| MDCK (NBL-2) | dog | kidney | 400 (μg/ml) | |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 1200 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| COS-1 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| Namalwa KJM-1 | Dulbecco's modified Eagle's medium | 600 (μg/ml) | ||
| COX-2 | RPMI 1640 Medium | 350 (μg/ml) | ||
| 293 | human | kidney; fetal | Minimal essential medium | 400 (μg/ml) |
| GLC-45 | Dulbecco's modified Eagle's medium | 600 (μg/ml) | ||
| CHO-K1 | hamster, Chinese | ovary | DMEM / F 12 medium | 600 (μg/ml) |
| COS-1 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| U-2 OS | human | bone; osteosarcoma | 400 (μg/ml) | |
| COS-1 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| N2a | Dulbecco's modified Eagle's medium | 560 (μg/ml) | ||
| COS-1 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| MDCK (NBL-2) | dog | kidney | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| Neuro-2a | mouse | brain; neuroblast; neuroblastoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 1400 (μg/ml) |
| DT40 | chicken | bursa; lymphoma | RPMI 1640 Medium | 1000 (μg/ml) |
| HeLa S3 | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 300 (μg/ml) |
| SIRC (Statens Seruminstitut Rabbit Cornea) | rabbit | eye (cornea) | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 200 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Minimal essential medium | 1000 (μg/ml) |
| ES-E14TG2a | mouse | embryonic stem cell; pluripotent; HGRPT deficient | 200 (μg/ml) | |
| HeLa S3 | human | cervix; adenocarcinoma | 800 (μg/ml) | |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Minimal essential medium | 0.1 (μg/ml) |
| MDA-MB-435 | human | breast | Minimal essential medium | 1000 (μg/ml) |
| RD | human | muscle; rhabdomyosarcoma | Dulbecco's modified Eagle's medium | 100 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | RPMI 1640 Medium | 100 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 1000 (μg/ml) |
| CRFK | cat | kidney (cortex) | Dulbecco's modified Eagle's medium | 2000 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 2000 (μg/ml) |
| H1299 | human | lung | RPMI 1640 Medium | 500 (μg/ml) |
| Hep 3B2.1-7 | human | liver; hepatocellular carcinoma | Minimal essential medium | 500 (μg/ml) |
| PLC/PRF/5 | human | liver; Alexander cells; hepatoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| Hep 3B2.1-7 | human | liver; hepatocellular carcinoma | Eagle's minimal essential medium | 2000 (μg/ml) |
| Hep 3B2.1-7 | human | liver; hepatocellular carcinoma | Minimal essential medium | 2 (mg/ml) |
| CHO/dhFr | hamster, Chinese | ovary; deficient in dihydrofolate reductase | α-modified minimal essential medium | 1000 (μg/ml) |
| CHO-K1 | hamster, Chinese | ovary | Ham’s F-12 nutrient mixture | 1500 (μg/ml) |
| K-562 | human | pleural effusion (metastatic); chronic myelo-genous leukemia (bone marrow primary) | Dulbecco's modified Eagle's medium | 850 (μg/ml) |
| Hs27 | human | skin (foreskin) | Dulbecco's modified Eagle's medium | 850 (μg/ml) |
| 32D Clone 3 | mouse | bone marrow | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Minimal essential medium | 800 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| CV-1 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| COLO 320DM | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 300 (μg/ml) |
| COLO 320HSR | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| COLO 320HSR | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| NIH/3T3 | mouse | embryo | 500 (μg/ml) | |
| FRTL | rat | thyroid | 600 (μg/ml) | |
| QT6 | quail, Japanese | fibrosarcoma | 800 (μg/ml) | |
| 32D Clone 3 | mouse | bone marrow | 1000 (μg/ml) | |
| 32D Clone 3 | mouse | bone marrow | 1000 (μg/ml) | |
| PC12 | Dulbecco's modified Eagle's medium | 700 (μg/ml) | ||
| 32D Clone 3 | mouse | bone marrow | 600 (μg/ml) | |
| SW480 | human | colon; colorectal adenocarcinoma | 500 (μg/ml) | |
| 32D Clone 3 | mouse | bone marrow | 200 (μg/ml) | |
| Bosc23 | 500 (μg/ml) | |||
| 293 | human | kidney; fetal | Minimal essential medium | 900 (μg/ml) |
| BJAB | RPMI 1640 Medium | 250 (μg/ml) | ||
| 293 | human | kidney; fetal | 250 (μg/ml) | |
| RBL-1 | rat | peripheral blood; basophil; leukemia | 400 (μg/ml) | |
| 32D Clone 3 | mouse | bone marrow | 800 (μg/ml) | |
| 32D Clone 3 | mouse | bone marrow | 800 (μg/ml) | |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| LLC-PK1 | pig | kidney | 500 (μg/ml) | |
| M1 | mouse | myeloblast; myeloid leukemia | 600 (μg/ml) | |
| COS-1 | monkey, African green | kidney | RPMI 1640 Medium | 400 (μg/ml) |
| COS-1 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| PC-12 | rat | adrenal gland; pheochromocytoma | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| 293T | human | Kidney (embryonic) | Dulbecco's modified Eagle's medium | 62500 (μg/ml) |
| MCF7 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| MV-4-11 | human | peripheral blood; biphenotypic B myelomonocytic leukemia | RPMI 1640 Medium | 400 (μg/ml) |
| MV-4-11 | human | peripheral blood; biphenotypic B myelomonocytic leukemia | RPMI 1640 Medium | 400 (μg/ml) |
| 32D Clone 3 | mouse | bone marrow | 400 (μg/ml) | |
| CHO-K1 | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| COS-1 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| Raji | human | B lymphocyte; Burkitt's lymphoma | RPMI 1640 Medium | 500 (μg/ml) |
| COS-7 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 50 (μg/ml) |
| NIH/3T3 | mouse | embryo | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| COS-7 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 750 (μg/ml) |
| 70Z/3 | mouse | pre-B lymphoblast; methylnitrosourea-induced lymphoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| COS-7 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | 400 (μg/ml) | |
| SiHa | human | cervix; squamous cell carcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| HeLa S3 | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| HT-1080 | human | connective tissue; fibrosarcoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| U-2 OS | human | bone; osteosarcoma | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| HeLa S3 | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 600 (μg/ml) |
| CHO | hamster, Chinese | ovary | Dulbecco's modified Eagle's medium | 750 (μg/ml) |
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 750 (μg/ml) |
| 293 | human | kidney; fetal | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| GH3 | rat | pituitary tumor | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| AKH13 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| 293-H | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| LMTK– | Dulbecco's modified Eagle's medium | 600 (μg/ml) | ||
| INS-1 | RPMI 1640 Medium | 500 (μg/ml) | ||
| LB831-BLC | Iscove's minimal essential medium | 2000 (μg/ml) | ||
| E14-1.1 | 720 (μg/ml) | |||
| SD1 | 500 (μg/ml) | |||
| 13-5-1 | Ham’s F-12 nutrient mixture | 800 (μg/ml) | ||
| CHO 22H11 | GMEM medium | 800 (μg/ml) | ||
| HeLa S | Dulbecco's modified Eagle's medium | 750 (μg/ml) | ||
| Jurkat | RPMI 1640 Medium | 250 (μg/ml) | ||
| HL3T1 | 2000 (μg/ml) | |||
| BJAB | RPMI 1640 Medium | 400 (μg/ml) | ||
| Ed141.MEL | RPMI 1640 Medium | 800 (μg/ml) | ||
| Ed147.BT | DMEM / F 12 medium | 400 (μg/ml) | ||
| Ed149.BT | DMEM / F 12 medium | 800 (μg/ml) | ||
| CSM14.1 | 2000 (μg/ml) | |||
| ES cell | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| Jurkat, Clone E6-1 | human | T lymphocyte; acute T cell leukemia | RPMI 1640 Medium | 250 (μg/ml) |
| 13-5-1 | 500 (μg/ml) | |||
| EUFA592 | RPMI 1640 Medium | 300 (μg/ml) | ||
| EUFA816 | RPMI 1640 Medium | 500 (μg/ml) | ||
| EUFA961 | RPMI 1640 Medium | 250 (μg/ml) | ||
| EUFA696 | RPMI 1640 Medium | 500 (μg/ml) | ||
| AG656 | RPMI 1640 Medium | 500 (μg/ml) | ||
| BD952 | RPMI 1640 Medium | 500 (μg/ml) | ||
| EUFA696 | RPMI 1640 Medium | 1000 (μg/ml) | ||
| EUFA543 | RPMI 1640 Medium | 300 (μg/ml) | ||
| MT58 | Ham’s F-12 nutrient mixture | 700 (μg/ml) | ||
| N18TG2 | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| U373 | human | Glioblastoma-astrocytoma | 500 (μg/ml) | |
| C3H10T1/2 | mouse | embryonic mesenchymal cell line | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| QSG7701 | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| TMK-1 | RPMI 1640 Medium | 500 (μg/ml) | ||
| MEFs | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| SC-2 | Schneider’s insect medium | 2000 (μg/ml) | ||
| S2-O13 | Minimal essential medium | 300 (μg/ml) | ||
| Caco-2 | human | colon; colorectal adenocarcinoma | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| Tet-off HT-1080 | Dulbecco’s modified minimal essential medium | 600 (μg/ml) | ||
| UM-SCC | 1000 (μg/ml) | |||
| HCT 116 | human | colon; colorectal carcinoma | 400 (μg/ml) | |
| N18–RE 105 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| Pam 212 | Eagle's minimal essential medium | 300 (μg/ml) | ||
| LY-2 | Eagle's minimal essential medium | 600 (μg/ml) | ||
| LY-8 | Eagle's minimal essential medium | 800 (μg/ml) | ||
| HCT 116 | human | colon; colorectal carcinoma | DMEM / F 12 medium | 400 (μg/ml) |
| PS120 | 500 (μg/ml) | |||
| hBRIE 380i-neg | Iscove's modified Dulbecco's medium | 300 (μg/ml) | ||
| Huh-7 | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| Chang Liver | human | HeLa contaminant | Dulbecco's modified Eagle's medium | 350 (μg/ml) |
| MCF-7 | human | Dulbecco's modified Eagle's medium | 600 (μg/ml) | |
| 1074MEL | RPMI 1640 Medium | 600 (μg/ml) | ||
| 1106MEL | RPMI 1640 Medium | 500 (μg/ml) | ||
| 1174MEL | RPMI 1640 Medium | 500 (μg/ml) | ||
| Hep G2 | human | liver; hepatocellular carcinoma | RPMI 1640 Medium | 800 (μg/ml) |
| CCLP1 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| V79/SD1 | Dulbecco's modified Eagle's medium | 600 (μg/ml) | ||
| CL1-0 | RPMI 1640 Medium | 500 (μg/ml) | ||
| IEC-17 | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| CL1-5 | RPMI 1640 Medium | 1000 (μg/ml) | ||
| K562-9 | RPMI 1640 Medium | 1000 (μg/ml) | ||
| NIH3T3 | mouse | embryo | 1000 (μg/ml) | |
| MEFs | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| Evsa-T | Dulbecco's modified Eagle's medium | 300 (μg/ml) | ||
| PC-12 | rat | adrenal gland; pheochromocytoma | Dulbecco's modified Eagle's medium | 400 (μg/ml) |
| β-STC-1 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| SK-N-SH | human | bone marrow (metastasis); neuroblastoma (brain primary) | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| SK-N-MC | human | supraorbital area (metastasis); neuroepithelioma (brain primary) | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| SK-N-MC-IXC | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| LCC-18 | RPMI 1640 Medium | 400 (μg/ml) | ||
| LCC-18 | RPMI 1640 Medium | 400 (μg/ml) | ||
| L929sA | Dulbecco's modified Eagle's medium | 100 (μg/ml) | ||
| IOSE-398 | 350 (μg/ml) | |||
| GH3 | rat | pituitary tumor | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| OK-P | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| RCC-4 | Dulbecco's modified Eagle's medium | 100 (μg/ml) | ||
| rHSCs | Dulbecco's modified Eagle's medium | 600 (μg/ml) | ||
| LY-B | 2000 (μg/ml) | |||
| REF | Dulbecco's modified Eagle's medium | 2000 (μg/ml) | ||
| TPC-1 | Ham’s F-12 nutrient mixture | 2000 (μg/ml) | ||
| WRO | Ham’s F-12 nutrient mixture | 500 (μg/ml) | ||
| FRO | Ham’s F-12 nutrient mixture | 500 (μg/ml) | ||
| BCBL-1 | RPMI 1640 Medium | 1000 (μg/ml) | ||
| NPC-KT | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| MDCKts.src | 830 (μg/ml) | |||
| S100L | 830 (μg/ml) | |||
| S137L | 500 (μg/ml) | |||
| LPS449 | 900 (μg/ml) | |||
| FTC-238 | 830 (μg/ml) | |||
| K562 | human | lymphoblastoid | 1000 (μg/ml) | |
| ES cell | 700 (μg/ml) | |||
| U-937 | human | macrophage; histiocytic lymphoma | α-modified minimal essential medium | 400 (μg/ml) |
| β1A-GD25 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| GD25T | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| HUES-7 | Dulbecco's modified Eagle's medium | 600 (μg/ml) | ||
| T47D-Y | Minimal essential medium | 600 (μg/ml) | ||
| T47DC42 | Minimal essential medium | 150 (μg/ml) | ||
| MCF-7C4-12 | Minimal essential medium | 300 (μg/ml) | ||
| HeLa-TO | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| mature embryos of sgr seeds | 1000 (μg/ml) | |||
| COS-7 | monkey, African green | kidney | Dulbecco's modified Eagle's medium | 500 (μg/ml) |
| MEFs | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| RMA-S | 500 (μg/ml) | |||
| KNS-81 | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| KM12SM | 1000 (μg/ml) | |||
| KB-3-1 | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| PC-3M | RPMI 1640 Medium | 500 (μg/ml) | ||
| Co115 | RPMI 1640 Medium | 500 (μg/ml) | ||
| Co115 | RPMI 1640 Medium | 500 (μg/ml) | ||
| Co115 | RPMI 1640 Medium | 1200 (μg/ml) | ||
| ARCaP | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| 721.221 | RPMI 1640 Medium | 1500 (μg/ml) | ||
| SGC7901 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| VSMCs | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| U251 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| GM5849 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| GM637 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| L929 | 500 (μg/ml) | |||
| BE11 | 1500 (μg/ml) | |||
| CMK | RPMI 1640 Medium | 800 (μg/ml) | ||
| GT1-7 | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| AUXB1 | 500 (μg/ml) | |||
| HA1 | 400 (μg/ml) | |||
| GM7372 | α-modified minimal essential medium | 400 (μg/ml) | ||
| DC-3F/ADII | 200 (μg/ml) | |||
| K562 | human | lymphoblastoid | RPMI 1640 Medium | 400 (μg/ml) |
| L1.2 | RPMI 1640 Medium | 500 (μg/ml) | ||
| ROS 17/2.8 | DMEM / F 12 medium | 500 (μg/ml) | ||
| Jurkat T | RPMI 1640 Medium | 600 (μg/ml) | ||
| Jurkat T | RPMI 1640 Medium | 600 (μg/ml) | ||
| HeLa Tet-On | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| HeLa Tet-On | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| RCCD1 | 800 (μg/ml) | |||
| HHUA | Dulbecco's modified Eagle's medium | 1200 (μg/ml) | ||
| Ishikawa | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| CGR8 | BHK21 medium | 1000 (μg/ml) | ||
| INS-1 832/13 | RPMI 1640 Medium | 600 (μg/ml) | ||
| DO11.10 | 500 (μg/ml) | |||
| CEM/ARAC-8C | RPMI 1640 Medium | 400 (μg/ml) | ||
| BaF3 | RPMI 1640 Medium | 400 (μg/ml) | ||
| High Five | 400 (μg/ml) | |||
| DCEK.ICAM.Hi7 | RPMI 1640 Medium | 800 (μg/ml) | ||
| 3Y1 | Dulbecco's modified Eagle's medium | 400 (μg/ml) | ||
| Ba/F3 | RPMI 1640 Medium | 800 (μg/ml) | ||
| BaF3 | 800 (μg/ml) | |||
| Ba/F3 | RPMI 1640 Medium | 800 (μg/ml) | ||
| NR | 500 (μg/ml) | |||
| Ba/F3 | IL-3 conditioned medium | 500 (μg/ml) | ||
| Ba/F3 | IL-3 conditioned medium | 1000 (μg/ml) | ||
| SQ20B | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| IDG26.10-3 | 1000 (μg/ml) | |||
| P1.PyT | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| BaF3 | 1000 (μg/ml) | |||
| DBA/1 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| HepKANO | 800 (μg/ml) | |||
| FDCW2 | OPTI-MEM | 800 (μg/ml) | ||
| HeLa | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| DG44 | α-modified minimal essential medium | 800 (μg/ml) | ||
| PG13 | mouse | embryo; retroviral packaging line | 700 (μg/ml) | |
| HeLa T-REx | Dulbecco's modified Eagle's medium | 500 (μg/ml) | ||
| Jurkat | 600 (μg/ml) | |||
| K562 | human | lymphoblastoid | RPMI 1640 Medium | 800 (μg/ml) |
| K562 | human | lymphoblastoid | RPMI 1640 Medium | 350 (μg/ml) |
| Psi-2 | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| PA317 | mouse | embryo; amphotropic retroviral packaging line | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| HeLa-Munc18b | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| HEK-293-Munc18b | Dulbecco's modified Eagle's medium | 10 (μg/ml) | ||
| 2GP19Talf | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| Schwann cell | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| AKR-2B | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| PANC-1 | human | pancreas (duct); epithelioid carcinoma | Dulbecco's modified Eagle's medium | 800 (μg/ml) |
| HeLa S3 | human | cervix; adenocarcinoma | Ham’s F-12 nutrient mixture | 700 (μg/ml) |
| HeLa S3 | human | cervix; adenocarcinoma | Dulbecco's modified Eagle's medium | 700 (μg/ml) |
| REF-52 | 700 (μg/ml) | |||
| TM87-16 | 700 (μg/ml) | |||
| STM91-01 | 700 (μg/ml) | |||
| HeLa S3 | human | cervix; adenocarcinoma | 700 (μg/ml) | |
| BCaP-37 | 400 (μg/ml) | |||
| LK2 | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| L929 | Minimal essential medium | 800 (μg/ml) | ||
| HeLa/CL 12 | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| EcR-293 | Dulbecco's modified Eagle's medium | 200 (μg/ml) | ||
| HeLa Tet-On | Dulbecco's modified Eagle's medium | 200 (μg/ml) | ||
| KYSE | RPMI-1640 / Ham's F-12 | 1000 (μg/ml) | ||
| NB4-S1 | RPMI 1640 Medium | 800 (μg/ml) | ||
| RECs | 2000 (μg/ml) | |||
| Jurkat T | RPMI 1640 Medium | 500 (μg/ml) | ||
| HaCaT | Dulbecco's modified Eagle's medium | 1000 (μg/ml) | ||
| HaCaT | Dulbecco's modified Eagle's medium | 800 (μg/ml) | ||
| Jurkat | 600 (μg/ml) | |||
| BJAB | RPMI 1640 Medium | 1000 (μg/ml) | ||
| BJAB | RPMI 1640 Medium | 600 (μg/ml) | ||
| A20 | mouse | B lymphocyte; reticulum cell sarcoma | Dulbecco's modified Eagle's medium | 1000 (μg/ml) |
| NPM-ALK Tet-Off MEF | DMEM | 500 (μg/ml) |